Urothelial Cancer Drugs Market To Reach $6.78 Billion By 2030

January 2025 | Report Format: Electronic (PDF)

Urothelial Cancer Drugs Market Growth & Trends

The global urothelial cancer drugs market size is estimated to reach USD 6.78 billion by 2030, registering a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Availability of novel drugs, the presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.

Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions such as North America and Europe. The disease has the highest lifetime cost of care per patient among all tumors in the U.S. due to its high relapse rate and invasive lifelong monitoring including cystoscopy follow-ups.

Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases. Urothelial cancer is clinically divided into three categories: non-muscle invasive bladder cancer (NMIBC, early-stage), muscle-invasive disease (MIBC, mid-stage), and metastatic disease (late-stage). At diagnosis, approximately 70% of cases are non-muscle invasive disease, 20% are at the muscle-invasive stage, and 10% are at the advanced stage.

key Request a free sample copy or view report summary: Urothelial Cancer Drugs Market Report

Urothelial Cancer Drugs Market Report Highlights

The urothelial carcinoma segment accounted for 57.5% of the market revenue in 2023, dominance is further reinforced by advancements in targeted therapies and immunotherapies.
By treatment, the immunotherapy segment held the largest revenue share in the global market in 2023, attributed to the success of immune checkpoint inhibitors.
In 2023, the hospital segment dominated the market, driven by the availability of multidisciplinary teams that can offer personalized treatment plans tailored to individual patient needs.
The U.S. dominated the market, with more than 37.7% of the market in 2023, driven by a high prevalence of bladder cancer and the availability of advanced treatment options.